Tectonic Therapeutic Inc.
TECX
Get informed when a big investor buys or sells
+ FollowMarket Cap$672.12M
Close$
$13.78
55.2% downside
Current Fair Value
55.2% downsideOvervalued by 55.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $672.12 Million |
|---|---|
| Enterprise Value | $449.45 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-4.05 |
| Beta | 0.22 |
| Outstanding Shares | 18,964,008 |
Return
| Return on Equity | -38.32% |
|---|---|
| Return on Assets | -36.19% |
| Return on Invested Capital | -39.86% |
Valuation & Multiples
| P/E Ratio | -7.79 |
|---|---|
| PEG | -67.69 |
| Price to Sales | - |
| Price to Book Ratio | 2.8 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -4.97 |
| Enterprise Value to Net Income | -6 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.02 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 19, 2026
EPS Estimate
$-1.29
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$-1.32
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0601▲ 0.97% |
|---|---|
| Total Calls | 193,100▼ 52.13% |
| Total Puts | 11,600▼ 42.86% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 74.60%▼ 0.78% |
|---|---|
| Total Invested | $481.17M▲ 12.73% |
| Investors Holding | 128▲ 12.00% |
ESG Score
No data
About Tectonic Therapeutic Inc.
clinical stage company focused on delivering step-change cell & gene therapies targeting cancer and rare disease.